Ceritinib-d7

Modify Date: 2024-01-22 21:38:45

Ceritinib-d7 structure	Common Name	Ceritinib-d7
	CAS Number	1632484-77-5	Molecular Weight	565.18
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₈H₂₉D₇ClN₅O₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Ceritinib-d7

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

Name	Ceritinib D7

Description	Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ALK Signaling Pathways >> Protein Tyrosine Kinase/RTK >> IGF-1R Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Insulin Receptor
References	[1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90.

Molecular Formula	C₂₈H₂₉D₇ClN₅O₃S
Molecular Weight	565.18